# Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma

> **NCT01022918** · PHASE2 · COMPLETED · sponsor: **Centre Georges Francois Leclerc** · enrollment: 134 (actual)

## Conditions studied

- Naive Unresectable Glioblastoma

## Interventions

- **DRUG:** Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)
- **DRUG:** Temodal/radiotherapy

## Key facts

- **NCT ID:** NCT01022918
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-07
- **Final completion:** 2011-01
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2012-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022918, "Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01022918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*